Oxford Global Conferences – 8th Annual Biomarkers Congress

250 delegates representing leading biotech companies, global pharma organisations and internationally renowned academic institutions

55 presentations, case studies and panel discussions focused on the key issues in biomarker research, personalised healthcare and companion diagnostics

6 Interactive Streams:

Biomarker Discovery & Development

Companion Diagnostics & Personalised Medicine

Biomarkers in Clinical Development

Enabling Technologies & Identification

CNS Biomarkers

CNS Case Studies

14 pre-scheduled one to one meetings, exhibition and informal networking opportunities

Oxford Global Conferences are proud to present the 8^th Annual Biomarkers Congress & 2^nd Annual CNS Biomarkers Congress, taking place on 19 & 20 February 2013 in Manchester.

The biomarker industry was worth over $13 billion in 2011 and its value is expected to double over the next 5 years. This event offers informed insights into the collaborative working methods, enabling technologies and clinical advances that bridge the gap between scientific innovation and tangible progress.

The 8th Annual Biomarkers Congress covers the key challenges and critical opportunities in go/no go decision making in early development and the integration of biomarkers into clinical development. Delegates will hear from the prominent decision makers in Rx/Dx co-development and personalised healthcare strategy for the oncology, respiratory and inflammation areas. Our expert speaker panel will also discuss the latest innovations in genomic and epigenetic biomarker discovery, along with the regulatory strategies needed to utilise advancing sequencing technologies within the scope of existing US and EU compliance frameworks.

The 2nd Annual CNS Biomarkers Congress features presentations on CNS study design for small patient populations, CSF markers for neurodegeneration and neuropsychiatric imaging technologies. Our internationally renowned speakers will also discuss the latest developments in neuroscience biomarkers through a series of industry and academic case studies.

Both events have earned a reputation for valuable networking opportunities and forward thinking debate. The combination of industry-led presentations, scientific discussions and partnering meetings creates a significant learning opportunity and measurable business benefit for the 250 pre-selected delegates in attendance.